trending Market Intelligence /marketintelligence/en/news-insights/trending/QXCCXZIhyL-25sG1hXTzNw2 content esgSubNav
Log in to other products

 /

Looking for more?

Contact Us
In This List

AgeX Therapeutics starts operations with $10M in equity financing
Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


AgeX Therapeutics starts operations with $10M in equity financing

BioTime Inc. subsidiary AgeX Therapeutics Inc. raised $10 million through an equity financing to fund its operations.

BioTime, IBS Capital LLC, KIZOO Technology Capital GmbH and certain individual investors participated in the financing.

BioTime continues to own about 87% of AgeX's shares. AgeX was created in April to consolidate certain subsidiaries and programs in the field of interventional gerontology, the treatment of age-related diseases.

BioTime's co-CEO, Michael West, will serve as AgeX's CEO.